{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:35:13Z","timestamp":1791250513413,"version":"4.1.0"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100014269","name":"Uniwersytet Medyczny w Bia\u0142ymstoku","doi-asserted-by":"publisher","award":["B.SUB.24.236"],"award-info":[{"award-number":["B.SUB.24.236"]}],"id":[{"id":"10.13039\/501100014269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s43440-025-00715-8","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T02:07:27Z","timestamp":1742177247000},"page":"543-560","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Polypharmacology: new drugs in 2023\u20132024"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2416-6039","authenticated-orcid":false,"given":"Piotr","family":"Ryszkiewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7057-8153","authenticated-orcid":false,"given":"Barbara","family":"Malinowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7708-6998","authenticated-orcid":false,"given":"Eberhard","family":"Schlicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"issue":"3","key":"715_CR1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11095-024-03656-8","volume":"41","author":"M Rafehi","year":"2024","unstructured":"Rafehi M, M\u00f6ller M, Ismail Al-Khalil W, Stefan SM. Medicinal polypharmacology in the clinic - translating the polypharmacolome into therapeutic benefit. Pharm Res. 2024;41(3):411\u20137. https:\/\/doi.org\/10.1007\/s11095-024-03656-8.","journal-title":"Pharm Res"},{"issue":"12","key":"715_CR2","doi-asserted-by":"publisher","first-page":"10374","DOI":"10.1021\/acs.jmedchem.4c00838","volume":"67","author":"V Lembo","year":"2024","unstructured":"Lembo V, Bottegoni G. Systematic investigation of dual-target-directed ligands. J Med Chem. 2024;67(12):10374\u201385. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00838.","journal-title":"J Med Chem"},{"issue":"1","key":"715_CR3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12964-024-01607-9","volume":"22","author":"A Doostmohammadi","year":"2024","unstructured":"Doostmohammadi A, Jooya H, Ghorbanian K, Gohari S, Dadashpour M. Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents. Cell Commun Signal. 2024;22(1):228. https:\/\/doi.org\/10.1186\/s12964-024-01607-9.","journal-title":"Cell Commun Signal"},{"issue":"5","key":"715_CR4","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2174\/1568026623666230126112628","volume":"23","author":"TC Rodrigues","year":"2023","unstructured":"Rodrigues TC, de Sousa NF, Dos Santos AMF, Guimar\u00e3es RD, Scotti MT, Scotti L. Challenges and discoveries in polypharmacology of neurodegenerative diseases. Curr Top Med Chem. 2023;23(5):349\u201370. https:\/\/doi.org\/10.2174\/1568026623666230126112628.","journal-title":"Curr Top Med Chem"},{"issue":"4","key":"715_CR5","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s43440-023-00501-4","volume":"75","author":"P Ryszkiewicz","year":"2023","unstructured":"Ryszkiewicz P, Malinowska B, Schlicker E. Polypharmacology: promises and new drugs in 2022. Pharmacol Rep. 2023;75(4):755\u201370. https:\/\/doi.org\/10.1007\/s43440-023-00501-4.","journal-title":"Pharmacol Rep"},{"key":"715_CR6","doi-asserted-by":"publisher","first-page":"106055","DOI":"10.1016\/j.phrs.2021.106055","volume":"176","author":"A Kabir","year":"2022","unstructured":"Kabir A, Muth A. Polypharmacology: the science of multi-targeting molecules. Pharmacol Res. 2022;176:106055. https:\/\/doi.org\/10.1016\/j.phrs.2021.106055.","journal-title":"Pharmacol Res"},{"issue":"10","key":"715_CR7","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.3324\/haematol.2023.284197","volume":"109","author":"C Tarantelli","year":"2024","unstructured":"Tarantelli C, Wald D, Munz N, Spriano F, Bruscaggin A, Cannas E, et al. Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy. Haematologica. 2024;109(10):3314\u201326. https:\/\/doi.org\/10.3324\/haematol.2023.284197.","journal-title":"Haematologica"},{"key":"715_CR8","doi-asserted-by":"publisher","first-page":"1419110","DOI":"10.3389\/fphar.2024.1419110","volume":"15","author":"SM Stefan","year":"2024","unstructured":"Stefan SM, Rafehi M. Medicinal polypharmacology-a scientific glossary of terminology and concepts. Front Pharmacol. 2024;15:1419110. https:\/\/doi.org\/10.3389\/fphar.2024.1419110.","journal-title":"Front Pharmacol"},{"issue":"9","key":"715_CR9","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1080\/17460441.2024.2376643","volume":"19","author":"L Manen-Freixa","year":"2024","unstructured":"Manen-Freixa L, Antolin AA. Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery. Expert Opin Drug Discov. 2024;19(9):1043\u201369. https:\/\/doi.org\/10.1080\/17460441.2024.2376643.","journal-title":"Expert Opin Drug Discov"},{"issue":"12","key":"715_CR10","doi-asserted-by":"publisher","first-page":"e2200190","DOI":"10.1002\/minf.202200190","volume":"41","author":"C Feldmann","year":"2022","unstructured":"Feldmann C, Bajorath J. Advances in computational polypharmacology. Mol Inf. 2022;41(12):e2200190. https:\/\/doi.org\/10.1002\/minf.202200190.","journal-title":"Mol Inf"},{"key":"715_CR11","doi-asserted-by":"publisher","first-page":"102771","DOI":"10.1016\/j.sbi.2023.102771","volume":"84","author":"A Cicho\u0144ska","year":"2024","unstructured":"Cicho\u0144ska A, Ravikumar B, Rahman R. AI for targeted polypharmacology: the next frontier in drug discovery. Curr Opin Struct Biol. 2024;84:102771. https:\/\/doi.org\/10.1016\/j.sbi.2023.102771.","journal-title":"Curr Opin Struct Biol"},{"issue":"1","key":"715_CR12","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1038\/s41467-024-47120-y","volume":"15","author":"BP Munson","year":"2024","unstructured":"Munson BP, Chen M, Bogosian A, Kreisberg JF, Licon K, Abagyan R, et al. De novo generation of multi-target compounds using deep generative chemistry. Nat Commun. 2024;15(1):3636. https:\/\/doi.org\/10.1038\/s41467-024-47120-y.","journal-title":"Nat Commun"},{"key":"715_CR13","unstructured":"vfa (Verband Forschender Arzneimittelhersteller). Innovationsbilanz 2023: Die neuen Medikamente und Anwendungsgebiete [Innovation balance 2023: The new drugs and areas of application]. https:\/\/www.vfa.de\/de\/arzneimittel-forschung\/woran-wir-forschen\/neue-medikamente-und-anwendungsgebiete-2023. Accessed 2 January 2025."},{"key":"715_CR14","unstructured":"vfa (Verband Forschender Arzneimittelhersteller). Innovationsbilanz 2024 [Innovation balance sheet 2024]. https:\/\/www.vfa.de\/de\/arzneimittel-forschung\/neuein-fuehrungen\/innovationsbilanz-2024. Accessed 2 January 2025."},{"key":"715_CR15","unstructured":"Pharmazeutische Zeitung, Arzneistoffe. Jahrgang 2023 [Drugs introduced in 2023] https:\/\/www.pharmazeutische-zeitung.de\/arzneistoff-jahrgang\/jahr\/2023\/. Accessed 2 January 2025."},{"key":"715_CR16","unstructured":"Pharmazeutische Zeitung, Arzneistoffe. Jahrgang 2024 [Drugs introduced in 2024] https:\/\/www.pharmazeutische-zeitung.de\/arzneistoff-jahrgang\/jahr\/2024\/. Accessed 2 January 2025."},{"issue":"1","key":"715_CR17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","volume":"63","author":"G Kanas","year":"2022","unstructured":"Kanas G, Ge W, Quek RGW, Keeven K, Nersesyan K, Jon E, Arnason. Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020\u20132025. Leuk Lymphoma. 2022;63(1):54\u201363. https:\/\/doi.org\/10.1080\/10428194.2021.1975188.","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"715_CR18","doi-asserted-by":"publisher","first-page":"7580","DOI":"10.3390\/ijms25147580","volume":"25","author":"LM Ju\u00e1rez-Salcedo","year":"2024","unstructured":"Ju\u00e1rez-Salcedo LM, Nimkar S, Coraz\u00f3n AM, Dalia S. Loncastuximab tesirine in the treatment of relapsed or refractory diffuse large B-cell lymphoma. Int J Mol Sci. 2024;25(14):7580. https:\/\/doi.org\/10.3390\/ijms25147580.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"715_CR19","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40265-021-01550-w","volume":"81","author":"A Lee","year":"2021","unstructured":"Lee A. Loncastuximab tesirine: first approval. Drugs. 2021;81(10):1229\u201333. https:\/\/doi.org\/10.1007\/s40265-021-01550-w.","journal-title":"Drugs"},{"key":"715_CR20","unstructured":"European Medicines Agency. Zynlonta\u00ae Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zynlonta-epar-product-information_en.pdf. Accessed 3 January 2025."},{"key":"715_CR21","doi-asserted-by":"publisher","unstructured":"Caimi PF, Hamadani M, Carlo-Stella C, Nickaeen M, Jordie E, Utsey K, et al. Understanding how CD19 expression levels impact the response to loncastuximab tesirine: a plain language summary. Future Oncol 2024 Nov 7:1\u201310. https:\/\/doi.org\/10.1080\/14796694.2024.2418751","DOI":"10.1080\/14796694.2024.2418751"},{"issue":"6","key":"715_CR22","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","volume":"22","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):790\u2013800. https:\/\/doi.org\/10.1016\/S1470-2045(21)00139-X.","journal-title":"Lancet Oncol"},{"issue":"3","key":"715_CR23","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3324\/haematol.2024.284973","volume":"110","author":"N Lin","year":"2025","unstructured":"Lin N, Sun X, Zhou H, Zou L, Zhou K, Liu L, et al. Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial. Haematologica. 2025;110(3):683\u201392. https:\/\/doi.org\/10.3324\/haematol.2024.284973.","journal-title":"Haematologica"},{"key":"715_CR24","doi-asserted-by":"publisher","first-page":"1295599","DOI":"10.3389\/fimmu.2023.1295599","volume":"14","author":"VS Radhakrishnan","year":"2024","unstructured":"Radhakrishnan VS, Davies AJ. Bispecific antibodies in indolent B-cell lymphomas. Front Immunol. 2024;14:1295599. https:\/\/doi.org\/10.3389\/fimmu.2023.1295599.","journal-title":"Front Immunol"},{"issue":"14","key":"715_CR25","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s40265-023-01930-4","volume":"83","author":"JE Frampton","year":"2023","unstructured":"Frampton JE. Epcoritamab: first approval. Drugs. 2023;83(14):1331\u201340. https:\/\/doi.org\/10.1007\/s40265-023-01930-4.","journal-title":"Drugs"},{"issue":"10","key":"715_CR26","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40265-023-01894-5","volume":"83","author":"M Shirley","year":"2023","unstructured":"Shirley M. Glofitamab: first approval. Drugs. 2023;83(10):935\u201341. https:\/\/doi.org\/10.1007\/s40265-023-01894-5.","journal-title":"Drugs"},{"key":"715_CR27","doi-asserted-by":"publisher","unstructured":"Davis JA, Granger K, Sakowski A, Goodwin S, Herbst A, Smith D, et al. Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma. Expert Rev Hematol 2023 Jul-Dec;16(12):915\u20138. https:\/\/doi.org\/10.1080\/17474086.2023.2285978","DOI":"10.1080\/17474086.2023.2285978"},{"key":"715_CR28","unstructured":"European Medicines Agency. Columvi\u00ae Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/columvi-epar-product-information_en.pdf. Accessed 3 January 2025."},{"key":"715_CR29","unstructured":"European Medicines Agency. Tepkinly\u00ae Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tepkinly-epar-product-information_en.pdf. Accessed 3 January 2025."},{"issue":"1","key":"715_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-024-01594-x","volume":"17","author":"A Rosenthal","year":"2024","unstructured":"Rosenthal A, Munoz J, Jun M, Wang T, Mutebi A, Wang A, et al. Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed\/refractory large B-cell lymphoma. J Hematol Oncol. 2024;17(1):69. https:\/\/doi.org\/10.1186\/s13045-024-01594-x.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"715_CR31","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.3390\/curroncol30050334","volume":"30","author":"BE Monteith","year":"2023","unstructured":"Monteith BE, Sandhu I, Lee AS. Management of multiple myeloma: a review for general practitioners in oncology. Curr Oncol. 2023;30(5):4382\u2013401. https:\/\/doi.org\/10.3390\/curroncol30050334.","journal-title":"Curr Oncol"},{"issue":"5","key":"715_CR32","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464\u201377. https:\/\/doi.org\/10.1001\/jama.2022.0003.","journal-title":"JAMA"},{"issue":"2","key":"715_CR33","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.3390\/curroncol30020179","volume":"30","author":"P Bhatt","year":"2023","unstructured":"Bhatt P, Kloock C, Comenzo R. Relapsed\/refractory multiple myeloma: a review of available therapies and clinical scenarios encountered in myeloma relapse. Curr Oncol. 2023;30(2):2322\u201347. https:\/\/doi.org\/10.3390\/curroncol30020179.","journal-title":"Curr Oncol"},{"issue":"1","key":"715_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM, et al. Multiple myeloma. Nat Rev Dis Primers. 2024;10(1):45. https:\/\/doi.org\/10.1038\/s41572-024-00529-7.","journal-title":"Nat Rev Dis Primers"},{"key":"715_CR35","doi-asserted-by":"publisher","unstructured":"Waldschmidt JM, Rasche L, Kort\u00fcm KM, Einsele H. Comprehensive review of bispecific antibody constructs in multiple myeloma: affinities, dosing strategies and future perspectives. Clin Lymphoma Myeloma Leuk. 2024 Nov 22:S2152-2650(24)02423-6. https:\/\/doi.org\/10.1016\/j.clml.2024.11.012","DOI":"10.1016\/j.clml.2024.11.012"},{"key":"715_CR36","unstructured":"European Medicines Agency. Talvey\u00ae Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/talvey-epar-product-information_en.pdf. Accessed 3 January 2025."},{"key":"715_CR37","unstructured":"European Medicines Agency. Tecvayli\u00ae Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecvayli-epar-product-information_en.pdf. Accessed 3 January 2025."},{"key":"715_CR38","unstructured":"European Medicines Agency. Elrexfio\u00ae Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/elrexfio-epar-product-information_en.pdf. Accessed 3 January 2025."},{"key":"715_CR39","doi-asserted-by":"publisher","unstructured":"Tang Y, Cain P, Anguiano V, Shih JJ, Chai Q, Feng Y. Impact of IgG subclass on molecular properties of monoclonal antibodies. MAbs. 2021 Jan-Dec;13(1):1993768. https:\/\/doi.org\/10.1080\/19420862.2021.1993768.","DOI":"10.1080\/19420862.2021.1993768"},{"issue":"24","key":"715_CR40","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodr\u00edguez-Otero P, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2204591.","journal-title":"N Engl J Med"},{"issue":"3","key":"715_CR41","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3324\/haematol.2023.283931","volume":"109","author":"L Liu","year":"2024","unstructured":"Liu L, Krishnan A. Talquetamab in multiple myeloma. Haematologica. 2024;109(3):718\u201324. https:\/\/doi.org\/10.3324\/haematol.2023.283931.","journal-title":"Haematologica"},{"issue":"1","key":"715_CR42","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-024-01611-z","volume":"17","author":"D Zhou","year":"2024","unstructured":"Zhou D, Wang Y, Chen C, Li Z, Xu K, Zhao K. Targeting GPRC5D for multiple myeloma therapy. J Hematol Oncol. 2024;17(1):88. https:\/\/doi.org\/10.1186\/s13045-024-01611-z.","journal-title":"J Hematol Oncol"},{"issue":"15","key":"715_CR43","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s40265-023-01945-x","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ. Talquetamab: first approval. Drugs. 2023;83(15):1439\u201345. https:\/\/doi.org\/10.1007\/s40265-023-01945-x.","journal-title":"Drugs"},{"issue":"16","key":"715_CR44","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s40265-022-01793-1","volume":"82","author":"C Kang","year":"2022","unstructured":"Kang C. Teclistamab: first approval. Drugs. 2022;82(16):1613\u20139. https:\/\/doi.org\/10.1007\/s40265-022-01793-1.","journal-title":"Drugs"},{"issue":"17","key":"715_CR45","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s40265-023-01954-w","volume":"83","author":"S Dhillon","year":"2023","unstructured":"Dhillon S. Elranatamab: first approval. Drugs. 2023;83(17):1621\u20137. https:\/\/doi.org\/10.1007\/s40265-023-01954-w.","journal-title":"Drugs"},{"issue":"6","key":"715_CR46","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/17474086.2024.2353751","volume":"17","author":"DC Moore","year":"2024","unstructured":"Moore DC, Granger K, Hill H, Karabinos A, Davis JA. Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed\/refractory multiple myeloma. Expert Rev Hematol. 2024;17(6):197\u2013200. https:\/\/doi.org\/10.1080\/17474086.2024.2353751.","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"715_CR47","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1007\/s12325-024-02797-x","volume":"41","author":"H Einsele","year":"2024","unstructured":"Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, et al. Comparative efficacy of talquetamab vs. current treatments in the locommotion and momment studies in patients with triple-class-exposed relapsed\/refractory multiple myeloma. Adv Ther. 2024;41(4):1576\u201393. https:\/\/doi.org\/10.1007\/s12325-024-02797-x.","journal-title":"Adv Ther"},{"issue":"5","key":"715_CR48","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.clml.2023.02.006","volume":"23","author":"MV Mateos","year":"2023","unstructured":"Mateos MV, Chari A, Usmani SZ, Goldschmidt H, Weisel K, Qi K, et al. Comparative efficacy of teclistamab versus physician\u2019s choice of therapy in the long-term follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS clinical trials in patients with triple-class exposed relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023;23(5):385\u201393. https:\/\/doi.org\/10.1016\/j.clml.2023.02.006.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"715_CR49","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1080\/10428194.2024.2313628","volume":"65","author":"I Mol","year":"2024","unstructured":"Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, et al. A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed\/refractory multiple myeloma. Leuk Lymphoma. 2024;65(5):660\u20138. Epub 2024 Feb 12. PMID: 38347747.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"715_CR50","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1007\/s10637-024-01476-6","volume":"42","author":"S Zhao","year":"2024","unstructured":"Zhao S, Wang W, Li J, Li Z, Liu Z, Zhang S, et al. Clinical research progress of fruquintinib in the treatment of malignant tumors. Invest New Drugs. 2024;42(6):612\u201322. https:\/\/doi.org\/10.1007\/s10637-024-01476-6.","journal-title":"Invest New Drugs"},{"issue":"4","key":"715_CR51","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/14656566.2024.2336069","volume":"25","author":"E Stucchi","year":"2024","unstructured":"Stucchi E, Bartolini M, Airoldi M, Fazio R, Dapr\u00e0 V, Mondello G, et al. Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence? Expert Opin Pharmacother. 2024;25(4):371\u201382. https:\/\/doi.org\/10.1080\/14656566.2024.2336069.","journal-title":"Expert Opin Pharmacother"},{"key":"715_CR52","unstructured":"European Medicines Agency. Fruzaqla\u00ae Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fruzaqla-epar-product-information_en.pdf. Accessed 3 January 2025."},{"issue":"10395","key":"715_CR53","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","volume":"402","author":"A Dasari","year":"2023","unstructured":"Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023;402(10395):41\u201353. https:\/\/doi.org\/10.1016\/S0140-6736(23)00772-9.","journal-title":"Lancet"},{"key":"715_CR54","doi-asserted-by":"publisher","unstructured":"Qurashi M, Vithayathil M, Khan SA. Epidemiology of cholangiocarcinoma. Eur J Surg Oncol. 2023 Sep;9:107064. https:\/\/doi.org\/10.1016\/j.ejso.2023.107064.","DOI":"10.1016\/j.ejso.2023.107064"},{"issue":"3","key":"715_CR55","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388(3):228\u201339. https:\/\/doi.org\/10.1056\/NEJMoa2206834.","journal-title":"N Engl J Med"},{"key":"715_CR56","doi-asserted-by":"publisher","first-page":"1509891","DOI":"10.3389\/fphar.2024.1509891","volume":"15","author":"J Guo","year":"2024","unstructured":"Guo J, Sun L, Chen Y, Ma J. Pemigatinib combined with immunotherapy and stereotactic body radiation therapy for FGFR2 fusion-positive advanced intrahepatic cholangiocarcinoma with brain metastasis: a case report. Front Pharmacol. 2024;15:1509891. https:\/\/doi.org\/10.3389\/fphar.2024.1509891.","journal-title":"Front Pharmacol"},{"key":"715_CR57","unstructured":"European Medicines Agency. Lytgobi\u00ae Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lytgobi-epar-product-information_en.pdf. Accessed 3 January 2025."},{"issue":"11","key":"715_CR58","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1093\/oncolo\/oyad149","volume":"28","author":"M Javle","year":"2023","unstructured":"Javle M, King G, Spencer K, Borad MJ. Futibatinib, an irreversible FGFR1-4 inhibitor for the treatment of FGFR-aberrant tumors. Oncologist. 2023;28(11):928\u201343. https:\/\/doi.org\/10.1093\/oncolo\/oyad149.","journal-title":"Oncologist"},{"issue":"5","key":"715_CR59","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.3390\/ijms24054522","volume":"24","author":"CL Alves","year":"2023","unstructured":"Alves CL, Ditzel HJ. Drugging the PI3K\/AKT\/mTOR pathway in ER\u2009+\u2009breast cancer. Int J Mol Sci. 2023;24(5):4522. https:\/\/doi.org\/10.3390\/ijms24054522.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"715_CR60","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/S1470-2045(23)00676-9","volume":"25","author":"IM Browne","year":"2024","unstructured":"Browne IM, Andr\u00e9 F, Chandarlapaty S, Carey LA, Turner NC. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer. Lancet Oncol. 2024;25(4):e139\u201351. https:\/\/doi.org\/10.1016\/S1470-2045(23)00676-9.","journal-title":"Lancet Oncol"},{"key":"715_CR61","unstructured":"European Medicines Agency. Truqap\u00ae Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/truqap-epar-product-information_en.pdf. Accessed 3 January 2025."},{"issue":"12","key":"715_CR62","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1177\/10600280241241531","volume":"58","author":"AJ Luboff","year":"2024","unstructured":"Luboff AJ, DeRemer DL. Capivasertib: a novel AKT inhibitor approved for hormone-receptor-positive, HER-2-negative metastatic breast cancer. Ann Pharmacother. 2024;58(12):1229\u201337. https:\/\/doi.org\/10.1177\/10600280241241531.","journal-title":"Ann Pharmacother"},{"issue":"22","key":"715_CR63","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388(22):2058\u201370. https:\/\/doi.org\/10.1056\/NEJMoa2214131.","journal-title":"N Engl J Med"},{"issue":"23","key":"715_CR64","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.3390\/cancers16234064","volume":"16","author":"HK Al-Ali","year":"2024","unstructured":"Al-Ali HK, Kuykendall AT, Ellis CE, Sampath J, Mesa R. Anemia in myelofibrosis: a focus on proactive management and the role of momelotinib. Cancers (Basel). 2024;16(23):4064. https:\/\/doi.org\/10.3390\/cancers16234064.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"715_CR65","doi-asserted-by":"publisher","first-page":"e70018","DOI":"10.1111\/cts.70018","volume":"17","author":"G Vlasakakis","year":"2024","unstructured":"Vlasakakis G, McCabe MT, Ho YL, Ferron-Brady G, Martin P, Bentley D, et al. Momelotinib: mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(8):e70018. https:\/\/doi.org\/10.1111\/cts.70018.","journal-title":"Clin Transl Sci"},{"issue":"5","key":"715_CR66","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/14656566.2024.2343780","volume":"25","author":"A Bruzzese","year":"2024","unstructured":"Bruzzese A, Martino EA, Labanca C, Mendicino F, Lucia E, Olivito V, et al. Momelotinib in myelofibrosis. Expert Opin Pharmacother. 2024;25(5):521\u20138. https:\/\/doi.org\/10.1080\/14656566.2024.2343780.","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"715_CR67","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1182\/blood.2023023719","volume":"144","author":"P Bose","year":"2024","unstructured":"Bose P. Momelotinib for the treatment of myelofibrosis. Blood. 2024;144(7):708\u201313. https:\/\/doi.org\/10.1182\/blood.2023023719.","journal-title":"Blood"},{"key":"715_CR68","unstructured":"European Medicines Agency. Omjjara\u00ae Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/omjjara-epar-product-information_en.pdf. Accessed 3 January 2025."},{"issue":"10373","key":"715_CR69","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","volume":"401","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet. 2023;401(10373):269\u201380. https:\/\/doi.org\/10.1016\/S0140-6736(22)02036-0.","journal-title":"Lancet"},{"issue":"34","key":"715_CR70","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","volume":"35","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-na\u00efve patients with myelofibrosis. J Clin Oncol. 2017;35(34):3844\u201350. https:\/\/doi.org\/10.1200\/JCO.2017.73.4418.","journal-title":"J Clin Oncol"},{"key":"715_CR71","doi-asserted-by":"publisher","first-page":"102266","DOI":"10.1016\/j.coi.2022.102266","volume":"80","author":"FW Miller","year":"2023","unstructured":"Miller FW. The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention. Curr Opin Immunol. 2023;80:102266. https:\/\/doi.org\/10.1016\/j.coi.2022.102266.","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"715_CR72","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jdermsci.2023.09.008","volume":"112","author":"T Dainichi","year":"2023","unstructured":"Dainichi T, Iwata M, Kaku Y. Alopecia areata: what\u2019s new in the epidemiology, comorbidities, and pathogenesis? J Dermatol Sci. 2023;112(3):120\u20137. https:\/\/doi.org\/10.1016\/j.jdermsci.2023.09.008.","journal-title":"J Dermatol Sci"},{"issue":"10","key":"715_CR73","doi-asserted-by":"publisher","first-page":"967","DOI":"10.36849\/JDD.SF396143","volume":"22","author":"A Tosti","year":"2023","unstructured":"Tosti A. Alopecia areata: the clinician and patient voice. J Drugs Dermatol. 2023;22(10):967\u201375. https:\/\/doi.org\/10.36849\/JDD.SF396143.","journal-title":"J Drugs Dermatol"},{"issue":"14","key":"715_CR74","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s40265-023-01928-y","volume":"83","author":"HA Blair","year":"2023","unstructured":"Blair HA, Ritlecitinib. First approval. Drugs. 2023;83(14):1315\u201321. https:\/\/doi.org\/10.1007\/s40265-023-01928-y.","journal-title":"Drugs"},{"key":"715_CR75","unstructured":"European Medicines Agency. Litfulo\u00ae Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/litfulo-epar-product-information_en.pdf. Accessed 3 January 2025."},{"issue":"10401","key":"715_CR76","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","volume":"402","author":"C Le Berre","year":"2023","unstructured":"Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023;402(10401):571\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(23)00966-2.","journal-title":"Lancet"},{"issue":"5","key":"715_CR77","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2217\/imt-2022-0255","volume":"15","author":"P Wils","year":"2023","unstructured":"Wils P, Peyrin-Biroulet L. Etrasimod for the treatment of ulcerative colitis. Immunotherapy. 2023;15(5):311\u201321. https:\/\/doi.org\/10.2217\/imt-2022-0255.","journal-title":"Immunotherapy"},{"issue":"2","key":"715_CR78","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40265-024-01997-7","volume":"84","author":"M Shirley","year":"2024","unstructured":"Shirley M. Etrasimod: first approval. Drugs. 2024;84(2):247\u201354. https:\/\/doi.org\/10.1007\/s40265-024-01997-7.","journal-title":"Drugs"},{"key":"715_CR79","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2147\/CEG.S391706","volume":"17","author":"K Glassner","year":"2024","unstructured":"Glassner K, Fan C, Irani M, Abraham BP. Therapeutic potential of etrasimod in the management of moderately-to-severely active ulcerative colitis: evidence to date. Clin Exp Gastroenterol. 2024;17:337\u201345. https:\/\/doi.org\/10.2147\/CEG.S391706.","journal-title":"Clin Exp Gastroenterol"},{"key":"715_CR80","unstructured":"European Medicines Agency. Velsipity\u00ae Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/velsipity-epar-product-information_en.pdf. Accessed 3 January 2025."},{"issue":"10383","key":"715_CR81","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","volume":"401","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur A, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401(10383):1159\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(23)00061-2.","journal-title":"Lancet"},{"issue":"1","key":"715_CR82","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40263-023-01059-8","volume":"38","author":"S Crisafulli","year":"2024","unstructured":"Crisafulli S, Boccanegra B, Carollo M, Bottani E, Mantuano P, Trifir\u00f2 G, et al. Myasthenia gravis treatment: from old drugs to innovative therapies with a glimpse into the future. CNS Drugs. 2024;38(1):15\u201332. https:\/\/doi.org\/10.1007\/s40263-023-01059-8.","journal-title":"CNS Drugs"},{"issue":"1","key":"715_CR83","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-023-01977-3","volume":"84","author":"M Shirley","year":"2024","unstructured":"Shirley M, Zilucoplan. First approval. Drugs. 2024;84(1):99\u2013104. https:\/\/doi.org\/10.1007\/s40265-023-01977-3.","journal-title":"Drugs"},{"key":"715_CR84","unstructured":"European Medicines Agency. Zilbrysq\u00ae Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zilbrysq-epar-product-information_en.pdf. Accessed 3 January 2025."},{"issue":"5","key":"715_CR85","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","volume":"22","author":"JF Howard Jr","year":"2023","unstructured":"Howard JF Jr, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023;22(5):395\u2013406. https:\/\/doi.org\/10.1016\/S1474-4422(23)00080-7.","journal-title":"Lancet Neurol"},{"issue":"1","key":"715_CR86","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.cld.2023.06.006","volume":"28","author":"I Houri","year":"2024","unstructured":"Houri I, Hirschfield GM. Primary biliary cholangitis: pathophysiology. Clin Liver Dis. 2024;28(1):79\u201392. https:\/\/doi.org\/10.1016\/j.cld.2023.06.006.","journal-title":"Clin Liver Dis"},{"issue":"9","key":"715_CR87","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2306185","volume":"390","author":"KV Kowdley","year":"2024","unstructured":"Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, et al. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med. 2024;390(9):795\u2013805. https:\/\/doi.org\/10.1056\/NEJMoa2306185.","journal-title":"N Engl J Med"},{"key":"715_CR88","doi-asserted-by":"publisher","unstructured":"Cumpian NA, Choi G, Saab S. Review of current and upcoming second-line treatments for primary biliary cholangitis. Dig Dis Sci. 2024 Dec 2. https:\/\/doi.org\/10.1007\/s10620-024-08742-w","DOI":"10.1007\/s10620-024-08742-w"},{"issue":"1","key":"715_CR89","doi-asserted-by":"publisher","first-page":"e16222","DOI":"10.1111\/liv.16222","volume":"45","author":"EG Giannini","year":"2025","unstructured":"Giannini EG, Pasta A, Calabrese F, Labanca S, Marenco S, Pieri G, et al. Second-line treatment for patients with primary biliary cholangitis: a systematic review with network meta-analysis. Liver Int. 2025;45(1):e16222. https:\/\/doi.org\/10.1111\/liv.16222.","journal-title":"Liver Int"},{"issue":"9","key":"715_CR90","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s40265-024-02075-8","volume":"84","author":"HA Blair","year":"2024","unstructured":"Blair HA. Elafibranor: first approval. Drugs. 2024;84(9):1143\u20138. https:\/\/doi.org\/10.1007\/s40265-024-02075-8.","journal-title":"Drugs"},{"key":"715_CR91","unstructured":"European Medicines Agency. Iqirvo\u00ae Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/iqirvo-epar-product-information_en.pdf. Accessed 3 January 2025."},{"issue":"1","key":"715_CR92","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1681\/ASN.0000000000000242","volume":"35","author":"K El Karoui","year":"2024","unstructured":"El Karoui K, Fervenza FC, De Vriese AS. Treatment of IgA nephropathy: a rapidly evolving field. J Am Soc Nephrol. 2024;35(1):103\u201316. https:\/\/doi.org\/10.1681\/ASN.0000000000000242.","journal-title":"J Am Soc Nephrol"},{"key":"715_CR93","unstructured":"European Medicines Agency. Filspari\u00ae Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/filspari-epar-product-information_en.pdf. Accessed 3 January 2025."},{"issue":"6","key":"715_CR94","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s40265-023-01864-x","volume":"83","author":"YY Syed","year":"2023","unstructured":"Syed YY. Sparsentan: first approval. Drugs. 2023;83(6):563\u20138. https:\/\/doi.org\/10.1007\/s40265-023-01864-x.","journal-title":"Drugs"},{"issue":"6","key":"715_CR95","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1080\/1744666X.2024.2319132","volume":"20","author":"H Trachtman","year":"2024","unstructured":"Trachtman H, Komers R, Inrig J. Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy. Expert Rev Clin Immunol. 2024;20(6):571\u20136. https:\/\/doi.org\/10.1080\/1744666X.2024.2319132.","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"715_CR96","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/13543784.2024.2414902","volume":"33","author":"H Nagasawa","year":"2024","unstructured":"Nagasawa H, Suzuki H, Ueda S, Suzuki Y. Dual blockade of endothelin A and angiotensin II type 1 receptors with sparsentan as a novel treatment strategy to alleviate IgA nephropathy. Expert Opin Investig Drugs. 2024;33(11):1143\u201352. https:\/\/doi.org\/10.1080\/13543784.2024.2414902.","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"715_CR97","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1177\/10600280231198925","volume":"58","author":"AW Chiu","year":"2024","unstructured":"Chiu AW, Bredenkamp N. Sparsentan: a first-in-class dual endothelin and angiotensin II receptor antagonist. Ann Pharmacother. 2024;58(6):645\u201356. https:\/\/doi.org\/10.1177\/10600280231198925.","journal-title":"Ann Pharmacother"},{"issue":"10451","key":"715_CR98","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(24)01027-4","volume":"404","author":"R Bissonnette","year":"2024","unstructured":"Bissonnette R, Warren RB, Pinter A, Agner T, Gooderham M, Schuttelaar MLA, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials. Lancet. 2024;404(10451):461\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(24)01027-4.","journal-title":"Lancet"},{"issue":"10","key":"715_CR99","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.medj.2024.08.009","volume":"5","author":"H Saeki","year":"2024","unstructured":"Saeki H, Kanda N. Treatment of chronic hand eczema with topical anti-inflammatory drugs other than topical corticosteroids. Med. 2024;5(10):1203\u20135. https:\/\/doi.org\/10.1016\/j.medj.2024.08.009.","journal-title":"Med"},{"issue":"3","key":"715_CR100","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/1744666X.2022.1993061","volume":"18","author":"MI Fardos","year":"2022","unstructured":"Fardos MI, Singh R, Perche PO, Kelly KA, Feldman SR. Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis. Expert Rev Clin Immunol. 2022;18(3):221\u201331. https:\/\/doi.org\/10.1080\/1744666X.2022.1993061.","journal-title":"Expert Rev Clin Immunol"},{"key":"715_CR101","unstructured":"European Medicines Agency. Anzupgo\u00ae Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/anzupgo-epar-product-information_en.pdf. Accessed 3 January 2025."},{"issue":"6","key":"715_CR102","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40265-020-01291-2","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S. Delgocitinib: first approval. Drugs. 2020;80(6):609\u201315. https:\/\/doi.org\/10.1007\/s40265-020-01291-2.","journal-title":"Drugs"},{"issue":"2","key":"715_CR103","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s40265-023-01992-4","volume":"84","author":"NL France","year":"2024","unstructured":"France NL, Syed YY. Tirzepatide: a review in type 2 diabetes. Drugs. 2024;84(2):227\u201338. https:\/\/doi.org\/10.1007\/s40265-023-01992-4.","journal-title":"Drugs"},{"key":"715_CR104","unstructured":"European Medicines Agency. Mounjaro\u00ae Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mounjaro-epar-product-information_en.pdf. Accessed 3 January 2025."},{"key":"715_CR105","doi-asserted-by":"publisher","unstructured":"Anderson SL, Marrs JC. Tirzepatide for type 2 diabetes. Drugs Context. 2023;12:2023-6-1. https:\/\/doi.org\/10.7573\/dic.2023-6-1","DOI":"10.7573\/dic.2023-6-1"},{"issue":"1","key":"715_CR106","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7570\/jomes22067","volume":"32","author":"R Sinha","year":"2023","unstructured":"Sinha R, Papamargaritis D, Sargeant JA, Davies MJ. Efficacy and safety of tirzepatide in type 2 diabetes and obesity management. J Obes Metab Syndr. 2023;32(1):25\u201345. https:\/\/doi.org\/10.7570\/jomes22067.","journal-title":"J Obes Metab Syndr"},{"issue":"6","key":"715_CR107","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2107519.","journal-title":"N Engl J Med"},{"issue":"9","key":"715_CR108","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","volume":"184","author":"PJ Rodriguez","year":"2024","unstructured":"Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, Brar R, Baker C, Gluckman TJ, Stucky NL. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern Med. 2024;184(9):1056\u201364. https:\/\/doi.org\/10.1001\/jamainternmed.2024.2525.","journal-title":"JAMA Intern Med"},{"issue":"8","key":"715_CR109","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1007\/s00415-023-11796-x","volume":"270","author":"M Chang","year":"2023","unstructured":"Chang M, Cai Y, Gao Z, Chen X, Liu B, Zhang C, et al. Duchenne muscular dystrophy: pathogenesis and promising therapies. J Neurol. 2023;270(8):3733\u201349. https:\/\/doi.org\/10.1007\/s00415-023-11796-x.","journal-title":"J Neurol"},{"issue":"6","key":"715_CR110","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.3233\/JND-230161","volume":"10","author":"MD Grounds","year":"2023","unstructured":"Grounds MD, Lloyd EM. Considering the promise of vamorolone for treating Duchenne muscular dystrophy. J Neuromuscul Dis. 2023;10(6):1013\u201330. https:\/\/doi.org\/10.3233\/JND-230161.","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"715_CR111","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40265-023-01986-2","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam SJ. Vamorolone: first approval. Drugs. 2024;84(1):111\u20137. https:\/\/doi.org\/10.1007\/s40265-023-01986-2.","journal-title":"Drugs"},{"key":"715_CR112","unstructured":"European Medicines Agency. Agamree\u00ae Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/agamree-epar-product-information_en.pdf. Accessed 25 January 2025."},{"key":"715_CR113","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07939-1","author":"MS Ibrahim","year":"2024","unstructured":"Ibrahim MS, Abdelwahab OA, Elawfi B, Ali FY, Amro S, Mohammed SF, et al. Meta-analysis of the efficacy and safety of vamorolone in Duchenne muscular dystrophy. Neurol Sci. 2024. https:\/\/doi.org\/10.1007\/s10072-024-07939-1.","journal-title":"Neurol Sci"},{"issue":"10","key":"715_CR114","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1001\/jamaneurol.2022.2480","volume":"79","author":"M Guglieri","year":"2022","unstructured":"Guglieri M, Clemens PR, Perlman SJ, Smith EC, Horrocks I, Finkel RS, et al. Efficacy and safety of vamorolone vs placebo and prednisone among boys with Duchenne muscular dystrophy: a randomized clinical trial. JAMA Neurol. 2022;79(10):1005\u201314. https:\/\/doi.org\/10.1001\/jamaneurol.2022.2480.","journal-title":"JAMA Neurol"},{"issue":"5","key":"715_CR115","doi-asserted-by":"publisher","first-page":"e208112","DOI":"10.1212\/WNL.0000000000208112","volume":"102","author":"UJ Dang","year":"2024","unstructured":"Dang UJ, Damsker JM, Guglieri M, Clemens PR, Perlman SJ, Smith EC, et al. Efficacy and safety of vamorolone over 48 weeks in boys with Duchenne muscular dystrophy: a randomized controlled trial. Neurology. 2024;102(5):e208112. https:\/\/doi.org\/10.1212\/WNL.0000000000208112.","journal-title":"Neurology"},{"issue":"44","key":"715_CR116","first-page":"3014","volume":"168","author":"BM Gensthaler","year":"2023","unstructured":"Gensthaler BM, Gr\u00e4fe KA, R\u00f6\u00dfler A, Siebenand S. Drei neulinge im Oktober [Three newly introduced drugs in October]. Pharm Ztg. 2023;168(44):3014\u201321.","journal-title":"Pharm Ztg"},{"key":"715_CR117","unstructured":"Gemeinsamer Bundesausschuss. The benefit assessment of medicinal products in accordance with the German Social Code, Book Five. https:\/\/www.g-ba.de\/english\/benefitassessment\/. Accessed 2 March 2025."},{"key":"715_CR118","unstructured":"Gemeinsamer Bundesausschuss. Tirzepatid und Ritlecitinib als Lifestyle-Arzneimittel gelistet [Listing tirzepatide and ritlecitinb as life-style drugs]. https:\/\/www.g-ba.de\/service\/fachnews\/150\/. Accessed 17 January 2025."},{"key":"715_CR119","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.2147\/DDDT.S358989","volume":"16","author":"L Wang","year":"2022","unstructured":"Wang L. Designing a dual GLP-1R\/GIPR agonist from tirzepatide: comparing residues between tirzepatide, GLP-1, and GIP. Drug Des Devel Ther. 2022;16:1547\u201359. https:\/\/doi.org\/10.2147\/DDDT.S358989.","journal-title":"Drug Des Devel Ther"},{"issue":"21","key":"715_CR120","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.1021\/jm058225d","volume":"48","author":"R Morphy","year":"2005","unstructured":"Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005;48(21):6523\u201343. https:\/\/doi.org\/10.1021\/jm058225d.","journal-title":"J Med Chem"},{"issue":"18","key":"715_CR121","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1021\/jm020138n","volume":"45","author":"N Murugesan","year":"2002","unstructured":"Murugesan N, Tellew JE, Gu Z, Kunst BL, Fadnis L, Cornelius LA, et al. Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists. J Med Chem. 2002;45(18):3829\u201335. https:\/\/doi.org\/10.1021\/jm020138n.","journal-title":"J Med Chem"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00715-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00715-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00715-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T10:04:31Z","timestamp":1747044271000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00715-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":121,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["715"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00715-8","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}